GLAUKOS Corp (GKOS) Q4 2024 Earnings Call

Concluded Feb 20, 2025

Feb 20, 2025

Period: FY2024 Q4
Runtime: —
Sources: 2 artifacts

Revenue · derived Q4 $105.50M +28.1% YoY

Gross margin · derived Q4 72.9% -4.2 pp YoY

Net income · derived Q4 -$33.58M

Open full screen 8-K 10-K

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.

2025 Financial Guidance 66 Reimbursement and Market Access 45 iDose TR Commercial Launch 41 U.S. Glaucoma Franchise 14 Non-iDose U.S. Revenue Pressure 10 International Growth 9

Management tone

Confident

Net tone +55 · moderate hedging

Grounding quotes

“Today, Glaukos reported record fourth quarter consolidated net sales of $105.5 million, up 28% versus the year ago quarter.”
“Our fourth quarter and full-year record results were primarily driven by both our U.S. and international glaucoma franchises, where we continue to accelerate efforts to pioneer and develop the interventional glaucoma, or IG, marketplace”
“While there is certainly more work to do here, particularly as we expand efforts into the commercial arena over the course of 2025 and beyond.”
“We foresee that a combination of LCD headwinds, volatility, and the expiration of the Hydrus royalty will result in flat to possibly low single-digit declines for our non-iDose revenues in 2025.”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Feb 20, 2025 10-K report Filed Feb 25, 2025

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →